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Abstract 
Background: The apolipoprotein B‑100 (ApoB‑100) transgenic mouse line is a model of human atherosclerosis. Lat‑
est findings suggest the importance of ApoB‑100 in the development of neurodegenerative diseases and microvas‑
cular/perivascular localization of ApoB‑100 protein was demonstrated in the cerebral cortex of ApoB‑100 transgenic 
mice. The aim of the study was to characterize cultured brain endothelial cells, pericytes and glial cells from wild‑type 
and ApoB‑100 transgenic mice and to study the effect of oxidized low‑density lipoprotein (oxLDL) on these cells.
Methods: Morphology of cells isolated from brains of wild type and ApoB‑100 transgenic mice was characterized 
by immunohistochemistry and the intensity of immunolabeling was quantified by image analysis. Toxicity of oxLDL 
treatment was monitored by real‑time impedance measurement and lactate dehydrogenase release. Reactive oxygen 
species and nitric oxide production, barrier permeability in triple co‑culture blood–brain barrier model and mem‑
brane fluidity were also determined after low‑density lipoprotein (LDL) or oxLDL treatment.
Results: The presence of ApoB‑100 was confirmed in brain endothelial cells, while no morphological change was 
observed between wild type and transgenic cells. Oxidized but not native LDL exerted dose‑dependent toxicity in all 
three cell types, induced barrier dysfunction and increased reactive oxygen species (ROS) production in both geno‑
types. A partial protection from oxLDL toxicity was seen in brain endothelial and glial cells from ApoB‑100 transgenic 
mice. Increased membrane rigidity was measured in brain endothelial cells from ApoB‑100 transgenic mice and in 
LDL or oxLDL treated wild type cells.
Conclusion: The morphological and functional properties of cultured brain endothelial cells, pericytes and glial cells 
from ApoB‑100 transgenic mice were characterized and compared to wild type cells for the first time. The membrane 
fluidity changes in ApoB‑100 transgenic cells related to brain microvasculature indicate alterations in lipid composi‑
tion which may be linked to the partial protection against oxLDL toxicity.
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Background
Cardiovascular diseases are the leading cause of death 
accounting for 48% of deaths worldwide. The main 
risk factor for cardiovascular diseases is atherosclero-
sis, which is associated with a permanently high level 
of serum very low density and low density lipoproteins 
(VLDL and LDL). Apolipoprotein B-100 (ApoB-100) is 
a 512  kDa glycoprotein, and the main apoprotein com-
ponent of VLDL and LDL particles which play a key role 
in the plasma lipid transport. Although earlier apolipo-
protein and cholesterol research was mainly focused 
on cardiovascular diseases, latest findings indicate that 
apoB-100 might be also involved in the development of 
neurodegenerative disorders. Recent studies show that 
the human neurodegenerative disorder, Alzheimer’s dis-
ease, is accompanied by elevated ApoB concentration 
in the serum [1, 2] and a high serum level of ApoB-100 
modulates cerebral amyloid deposition in vivo [3].
Previously, we have generated a transgenic mouse line 
overexpressing the human ApoB-100 protein [4]. This 
strain showed a significantly elevated serum triglyceride 
level on normal chow diet, and a significantly increased 
serum cholesterol level when fed on high fat diet com-
pared to wild-type littermates [5]. The hypercholester-
olemic ApoB-100 transgenic strain is frequently used as 
a model of atherosclerosis [6, 7]. Recently, we have shown 
that chronic hypertriglyceridemia led to the development 
of neurodegenerative changes in brains of ApoB-100 
transgenic mice. These changes include hyperphospho-
rylation of tau protein at several sites, extensive cortical 
and hippocampal neuronal apoptosis, marked reduction 
in the number and size of the dendritic spines in the hip-
pocampal neurons and impaired hippocampal presyn-
aptic functions [8]. Moreover, significant enlargement of 
brain ventricles in a transgene dose dependent manner 
was demonstrated by magnetic resonance imaging [9]. 
We have also shown that there is an extensive lipid per-
oxidation in the cortex and hippocampus of transgenic 
animals [10]. Besides the above mentioned neuropatho-
logical changes, a large decrease in the density of cortical 
microcapillary network was observed in transgenic com-
pared to wild-type mice [11].
In spite of the well-known contribution of ApoB-100 
to the development of hyperlipidemia and atherogenesis, 
there is less information on its presence and potential 
function in the brain. Previously, we have demonstrated 
that ApoB-100 protein is present in the cerebral cortex 
of mice overexpressing ApoB-100 [8] and shows micro-
vascular/perivascular localization [10]. However, little is 
known about the effect of ApoB-100 on the cells of the 
blood–brain barrier (BBB).
The aim of this study was to provide information on the 
expression and presence of ApoB-100 in endothelial cells, 
glial cells and pericytes in the cerebrovascular system in 
wild-type and transgenic mice. The effect of ApoB-100 on 
oxidized low-density lipoprotein (oxLDL)-induced cyto-
toxicity and on membrane fluidity of cerebral endothelial 
cells using various in vitro experimental approaches was 
investigated.
Methods
Materials
All reagents were purchased from Sigma-Aldrich Ltd., 
Hungary, unless otherwise indicated.
Animals
All animal studies were conducted following the 1998. 
XXVIII. Hungarian law and the EU Directive 2010/63/EU 
about animal protection and welfare. For animal experi-
ments official approvals have been obtained from our 
local animal health authority, the Governmental Office 
for Csongrád County, Directorate of Food Chain Safety 
and Animal Health (Permit numbers: XVI.02752/2009 
and XVI./834/2012).
For in  vitro studies primary cells were obtained from 
the ApoB-100 transgenic mouse line, a mouse model of 
human atherosclerosis [4]. F1 transgenic offsprings were 
backcrossed six times with C57BL/6J mice to ensure a 
more homogenous genetic background for appropriate 
comparative studies. Non-transgenic littermates were 
used as wild-type controls. Previously, it was demon-
strated that these transgenic animals fed on high cho-
lesterol diet developed severe coronary atherosclerosis 
by the age of 6 months [9]. Therefore during our experi-
ments all mice were at least 6 months old. Animals were 
fed on regular standard rodent chow and water ad  libi-
tum and kept under a 12 h light/12 h dark cycle. During 
the experiments all efforts were made to minimize animal 
suffering and pain.
In vitro mouse blood–brain barrier model
Primary mouse brain endothelial cell isolation was per-
formed using 6-month-old C57BL/6 wild type and trans-
genic mice based on methods from our group [12–14]. 
Animals were sacrificed with cervical dislocation. Mouse 
forebrains were collected in ice-cold sterile phosphate 
buffered saline (PBS). Meninges were removed using 
sterile filter paper and the tissue was cut into 1  mm3 
using a scalpel and digested with enzymes (1 mg/ml col-
lagenase type II and 15  µg/ml deoxyribonuclease type 
I, Roche, Switzerland) in Dulbecco’s modified Eagle 
medium (DMEM/F12, Gibco, Life Technologies, USA) 
at 37°C for 50  min. Microvessels were separated from 
myelin by centrifugation on a 20% bovine serum albu-
min (BSA)-DMEM gradient (1,000×g, 20 min, 3 times). 
The collected vessels were further digested by enzymes 
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(1  mg/ml collagenase–dispase and deoxyribonuclease 
type I in DMEM, both from Roche) for 35 min. Digested 
cerebral vessels were washed three times in cell culture 
medium then seeded onto Petri dishes (60 mm; Orange 
Scientific, Belgium) coated with collagen type IV and 
fibronectin. Mouse brain endothelial cells were cul-
tured in DMEM/F12 supplemented with plasma-derived 
bovine serum (15%; First Link, UK), heparin (100 µg/ml), 
basic fibroblast growth factor (1  ng/ml; Roche), insulin 
(5  µg/ml), transferrin (5  µg/ml), sodium selenite (5  ng/
ml), and gentamycin (50 µg/ml). Cells were grown under 
selective culture conditions for the first 4 days. Culture 
medium contained puromycin (3  µg/ml) to eliminate 
P-glycoprotein negative contaminating cell types [15]. 
When endothelial cells reached 90% confluency on the 
4th–5th day after seeding to the Petri dish, cells were 
subcultivated into 96-well plates (Corning, USA; ACEA, 
USA), cover slips (VWR, USA) and hanging cell culture 
inserts for different experiments, respectively. All sur-
faces were coated with collagen type IV and fibronec-
tin. Endothelial cells were passaged at a cell number of 
5 × 103 cells/well for 96-well plates and 3.5 × 104 cells/
cover slips. Since primary brain endothelial cell isola-
tion yield from mice is low compared to other species, 
24-well format culture inserts were used for perme-
ability studies (ThinCert, 24-well format, polyethylene 
terephthalate membrane, 0.33  cm2 surface, 3  µm pore 
size, Greiner Bio-one, Germany). These culture inserts 
were found to be appropriate for BBB permeability 
studies [16]. For barrier integrity tests endothelial cells 
were seeded to the luminal side of culture inserts at a 
cell number of 2.5  ×  104  cells/insert. To enhance BBB 
characteristics, primary mouse endothelial cells were 
co-cultured with primary mouse cerebral glial cells and 
pericytes [17].
Primary cultures of mouse pericytes were prepared by 
the same protocol as primary mouse brain endothelial 
cells, except for a shorter time of the second enzymatic 
digestion (15  min) and the omission of the puromycin 
treatment. At the end of the isolation process cerebral 
microvessels containing pericytes beside endothelial 
cells were seeded into collagen type IV coated 60  mm 
culture dishes (Orange Scientific, Belgium). After 4 days 
of culture in DMEM, 10% fetal bovine serum (FBS), and 
gentamycin (50  µg/ml) attached cells reached 70% of 
confluency. Pericytes were passaged into bigger, uncoated 
dishes (Orange Scientific, Belgium). Mouse pericyte cul-
tures were used at second passage and seeded at a cell 
number of 5 × 103 cells/well for 96-well plates, 3 × 104 
cells/cover slips and 5 × 103 cells/culture inserts. Primary 
mouse pericytes stain positive for α-smooth muscle actin 
but not for von Willebrand factor or glial fibrillary acidic 
protein (GFAP) [17, 18].
Primary mouse glial cells were obtained from 1 or 
2-day-old wild type or ApoB-100 transgenic mice [12, 
13]. Meninges were removed by fine forceps from brains. 
Little pieces of cortices were minced and mechanically 
dissociated by pressing the tissue through a nylon mesh 
(40 µm, Millipore, USA). Cell clusters were seeded onto 
uncoated 75 cm2 flasks (TPP, Germany) and cultured in 
DMEM containing FBS (10%; Lonza, Switzerland) and 
gentamycin (50  µg/ml) until 90% confluency. Glial cells 
were passaged at a cell number of 5 × 103 cells/well for 
96-well plates, 3  ×  104  cells/cover slips and 105  cells/
wells for 24-well plates (Greiner Bio-One, Germany). For 
the BBB co-culture model mixed glial cells were cultured 
for 2 weeks before use. Confluent glia cultures contained 
90% of astroglia (positive for GFAP), and 10% microglia 
(positive for CD11b).
To establish the triple co-culture BBB model culture 
inserts were put into 24-well plates containing confluent 
glia cultures. Mouse pericytes were subcultured to the 
under side of the culture membranes and mouse brain 
endothelial cells were passaged to the upper side of the 
coated inserts. Both compartments received endothe-
lial culture medium [17]. After 2 days of co-culture, cells 
were kept in culture medium containing 550 nM hydro-
cortisone and 10 mM lithium chloride [19, 20].
Treatment
Mouse endothelial cells, pericytes and glial cells were 
treated with native LDL (200  µg/ml) or oxLDL (50–
200 µg/ml) for 1 and 24 h in serum-free culture medium 
containing 1% BSA (fatty acid free) to avoid artefacts or 
biases caused by the lipid content of the serum. Both 
native and oxLDL were purified from human plasma and 
purchased from Biomedical Technologies Inc. (USA). 
In viability assays, Triton X-100 detergent was used at 
10  mg/ml concentration as a reference compound to 
cause cell death. For reactive oxygen species assay hydro-
gen peroxide (H2O2) and for the nitric oxide assay sodium 
nitroprusside (SNP) were used as positive controls. In all 
experiments, treatments were carried out carefully not to 
disturb cell monolayers when changing the medium.
Cell viability assays: real‑time monitoring of impedance 
and lactate dehydrogenase release
Impedance-based cell electronic sensing is a label-free, 
non-invasive technique for dynamic monitoring of the 
biological status of living cells. The RTCA-SP instrument 
(ACEA Biosciences, Inc., USA) registers the impedance 
of adherent cells automatically and continuously to quan-
tify cell proliferation and viability in real-time [21, 22]. 
E-plates (96-well culture plates with built in gold elec-
trodes) were coated with collagen type IV and fibronec-
tin for brain endothelial cells or with rat tail collagen for 
Page 4 of 16Lénárt et al. Fluids Barriers CNS  (2015) 12:17 
pericytes and glial cells at room temperature and dried 
for 40  min under UV and air-flow. Culture medium 
(60 μl) was added to each well for background measure-
ments, then 40 µl of cell suspension was pipetted into the 
wells. Cell density was 5 × 103 cells/well for all cell types. 
Cell growth was monitored until cells reached a steady 
phase, when they were treated with LDL or oxLDL. 
Impedance was monitored every 10 min. The cell index 
at each time point was defined as (Rn −  Rb)/15, where 
Rn is the cell-electrode impedance of the well when it 
contains cells and Rb is the background impedance of the 
well with the medium alone.
The presence of the intracellular enzyme, lactate dehy-
drogenase (LDH) in the culture supernatant is an indica-
tor of cell membrane damage. The concentration of LDH 
was determined using a commercially available kit (Cyto-
toxicity detection kit LDH, Roche, Switzerland). For LDH 
release assay brain endothelial cells, pericytes or glial 
cells were cultured in 96-well plates. After treatments 
culture supernatants (40 µl) were collected into another 
96-well plate and were incubated with equal amounts of 
reaction mixture for 20 min on a horizontal shaker. The 
enzyme reaction was stopped by 0.1 M HCl. Absorbance 
was measured at a wavelength of 492 nm with a multiwell 
plate reader (Fluostar Optima, BMG Labtechnologies, 
Germany). Cytotoxicity was calculated as percentage 
of the total LDH release from cells treated by 1% Triton 
X-100 detergent.
Detection of reactive oxygen species and nitric oxide 
production
For the measurement of reactive oxygen species (ROS) 
and nitric oxide (NO) production fluorometric detec-
tion probes were used. ROS was detected by chlorome-
thyl-dichloro-dihydro-fluorescein diacetate (DCFDA) 
and NO was detected by 4-amino-5-methylamino-
2′,7′-difluorofluorescein diacetate (DAF-FM, both from 
Molecular Probes, Life Technologies, USA). These indi-
cators penetrate the cell membrane by diffusion and 
interact with intracellular esterases to be activated. After 
DCFDA oxidation or reaction of DAF-FM with NO, 
fluorescent molecules are produced, and their signal is 
detectable and proportional to the produced ROS or NO. 
Confluent brain endothelial cells, pericytes or glial cells 
and were cultured in 96-well black-walled plates. After 
treatment cells were incubated with Ringer-Hepes buffer 
(118  mM NaCl, 4.8  mM KCl, 2.5  mM CaCl2, 1.2  mM 
MgSO4, 5.5 mM d-glucose, 10 mM Hepes, pH 7.4) con-
taining 2 µM DCFDA or 2 µM DAF-FM and 1.5 µM plu-
ronic acid (Life Technologies, Molecular Probes, USA) 
for 1 h at 37°C. Hydrogen peroxide treatment (100 µM) 
served as a positive control in the ROS assay and sodium 
nitroprusside (60 µM) treatment for the NO production. 
Fluorescence was measured by Fluostar Optima mul-
tiwell plate reader (BMG Labtechnologies, Germany) 
at 485  nm excitation and 520  nm emission wavelengths 
every 5 min for 1 h. Fluorescent values are presented as 
a percentage of the control group (cells receiving only 
treatment medium).
Measurement of barrier functions: resistance 
and permeability
Transendothelial electrical resistance (TEER) is an indi-
cator of the permeability of interendothelial tight junc-
tions; therefore it is a key parameter to validate BBB 
tightness in cell culture models. High TEER indicates 
models with a good paracellular barrier which can be 
used for permeability and transport experiments. TEER 
was measured by an EVOM resistance meter with cham-
ber electrodes appropriate for 24-well culture inserts 
(World Precision Instruments, USA) and it was expressed 
relative to the surface area of the monolayers (Ω  cm2). 
TEER was measured every day and the resistance value 
of cell-free inserts was subtracted from the measured val-
ues. Cells were treated with LDL and oxLDL on the 4th 
day of co-culture. The transendothelial penetration of 
Evans blue-labeled albumin (MW 67 kDa) was measured 
across the monolayers as previously described [12, 13]. 
Evans blue labels albumin effectively and can be used for 
tracking the penetration of albumin in tissues and across 
cell layers [23]. For permeability experiments, culture 
inserts were placed to 24-well plates (Greiner, Austria) 
containing 530 µl Ringer-Hepes buffer. In the upper com-
partment culture medium was replaced by 70 µl Ringer-
Hepes solution containing 1% BSA labeled with 165 µg/
ml Evans blue. The plates with inserts were slowly agi-
tated using a horizontal shaker (100 rpm; Biosan, Latvia) 
in the CO2 incubator for 1 h. During the assay at 20, 40 
and 60 min, inserts were moved to a new well containing 
Ringer Hepes buffer. Samples from the upper (luminal) 
and lower (abluminal) compartments were collected and 
the marker molecule content was measured at 584  nm 
excitation and 680  nm emission wavelengths (Fluostar 
Optima, BMG Labtechnologies, Germany). The albumin 
flux was also measured across cell-free inserts. Endothe-
lial permeability coefficient (Pe) was calculated as previ-
ously described [12, 24]. Clearance was expressed as μl 
of luminal compartment volume from which the tracer 
is completely cleared. The cleared volume was calculated 
from the concentration (C) of the tracer in the luminal 
and abluminal compartments and the volume (V) of 
the abluminal compartment (530  µl) by the following 
equation:
Cleared volume(µl) =
Cabluminal × Vabluminal
Cluminal
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The average cleared volume was plotted vs. time, 
and permeability-surface area product (PS) values for 
endothelial monolayers (PSe) were evaluated by the fol-
lowing equation:
PSe divided by the surface area (0.33  cm2) generated 
the Pe (10−6 cm/s).
Immunohistochemistry and quantification
Morphological comparison of primary cells derived from 
wild type and ApoB transgenic mice was performed 
using immunohistochemical staining. Endothelial cells 
were labeled for claudin-5, occludin, zonula occludens 
protein 1 (ZO-1) and β-catenin, pericytes for α-smooth 
muscle actin (α-SM) and astroglia for glial fibrillary acidic 
protein (GFAP). All cell types were also characterized for 
the presence of ApoB. Cells were grown on rat tail col-
lagen coated glass coverslips (1 cm2, borosilicate, VWR, 
USA). For claudin-5, ZO-1 and β-catenin staining, cells 
were fixed with cold acetone-methanol (1:1) for 10 min. 
For occludin, GFAP, α-SM and ApoB labeling cells were 
fixed with 3% paraformaldehyde for 30  min at room 
temperature and permeabilized with 0.5% Triton-X100. 
After fixation and permeabilization, cells were washed 
three times with PBS and non-specific binding sites were 
blocked with 3% BSA-PBS for 1  h at room temperature 
for all antibodies except for ApoB, for which cells were 
blocked with 5% rabbit serum (Dako, Denmark). Incuba-
tion with rabbit-anti-claudin-5, rabbit-anti-ZO-1, rab-
bit-anti-occludin (Life Technologies, Invitrogen, USA), 
mouse-anti-α-SM (Dako, Denmark), goat-anti-hApoB 
(Millipore, Germany), rabbit-anti-β-catenin and mouse-
anti-GFAP primary antibodies lasted overnight at 4°C. 
Cells were incubated with anti-rabbit secondary antibod-
ies labeled with CY3 or Alexa Fluor 488 (Life Technolo-
gies, USA), anti-mouse secondary antibodies Alexa Fluor 
555 or 488 (Life Technologies), anti-goat Alexa Fluor 
488 (Jackson ImmunoResearch Labs, USA) and H33343 
dye to stain nuclei for 1 h at room temperature. Between 
incubations cells were washed three times with PBS. 
Coverslips were mounted in Fluoromount-G (Southern 
Biotech, USA). Stainings were visualized by a Leica TCS 
SP5 confocal laser scanning microscope (Leica Microsys-
tems, Germany). At least eight non-overlapping pictures 
were captured for each cell type and staining from both 
wild type and transgenic mice. Digital image analy-
sis (512 ×  512 pixels, n =  8–16/group) was performed 
by using ImageJ, public domain software developed 
by the National Institutes of Health (USA) [13]. Immu-
nostained areas were defined by the threshold feature of 
ImageJ. After subtraction of the background fluorescence 
1
PSendothelial
=
1
PStotal
−
1
PSinsert
(subtraction of gray values of non-expressing pixels from 
every pixel) in the respective channel mean grayscale 
value was calculated and averaged.
Endothelial cells treated with 0, 100 and 200  µg/ml 
oxLDL for 24 h were also stained for junctional proteins 
claudin-5, occludin and β-catenin as described above. 
Double fluorescent nucleus staining by bis-benzimide 
and ethidium-homodimer-1 was performed on living 
cells as published in [22].
Measurement of plasma membrane fluidity in primary 
mouse brain endothelial cells
Brain endothelial cells from wild type and ApoB-100 
transgenic mice were treated overnight with 10  µg/ml 
LDL or 10  µg/ml oxLDL. Control cells received culture 
medium. After treatment, cells were collected by trypsi-
nization, washed once with PBS, resuspended in Ringer-
Hepes buffer and counted. The density of the cells for the 
membrane fluidity tests was optimized by absorbance 
measurement to OD360 =  0.05 (Hewlett Packard 8452A 
Diode Array Spectrophotometer). Cells were labeled with 
0.2  μM TMA-DPH (1-(4 trimethylammoniumphenyl)-
6-phenyl-1,3,5-hexatriene; Life Technologies, USA). 
Fluorescence anisotropy was measured on a T-format 
fluorescence spectrometer (Quanta Master QM-1, Pho-
ton Technology International, USA). Excitation and 
emission wavelengths were 360 and 430 nm (6 nm slits). 
Cells were kept under a continuous stirring at 37°C [25, 
26]. Anisotropy data were acquired in every second for 10 
min. After measuring baseline anisotropy, we introduced 
a strong membrane fluidizer, benzyl alcohol (30  mM, 
Merck, Germany) as a positive control. Transgenic and 
wild type data were calculated and plotted as treatment 
vs. fluorescent anisotropy.
Statistical analysis
Data are presented as mean  ±  SD. Statistical signifi-
cance between treatment groups was determined using 
one-way or two-way ANOVA following Dunnett or 
Bonferroni post-tests (GraphPad Prism 5.01; GraphPad 
Software, USA). Changes were considered statistically 
significant at p < 0.05 (*); p < 0.01 (**) and p < 0.001 (***). 
All experiments were repeated at least twice and the 
number of parallel samples varied between 4 and 8.
Results
Characterization of cultured brain endothelial cells, 
pericytes and glial cells from wild type and ApoB‑100 
transgenic mice by immunohistochemistry
Brain endothelial cells showed typical microvascu-
lar elongated morphology and formed confluent layers. 
Strong immunostaining was obtained for transmembrane 
tight junctional proteins claudin-5 and occludin, and 
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cytoplasmic linker proteins ZO-1 and β-catenin in both 
groups (Figure 1). Junctional labeling localized to endothe-
lial cell borders and cell–cell attachment was continu-
ous. Pericytes were characterized by their large cell size, 
polygonal cell shape, branched morphology and positive 
staining for α-SM actin. Actin bundles were clearly visible 
and typical for cultured brain pericytes [17, 27]. Astroglia 
cells expressing GFAP showed a multipolar shape and 
long processes. This stellate shape was present in both 
wild type and transgenic groups. Cellular morphology and 
immunostaining intensity of pericytes and glial cells from 
wild type animals were similar to those from ApoB-100 
transgenic mice. There were no significant differences in 
claudin-5 immunolabeling comparing wild type cells with 
ApoB-100 transgenic brain endothelial cells. The fluores-
cence intensity of cytoplasmic linker proteins ZO-1 and 
β-catenin staining was significantly higher in the trans-
genic group than in wild type endothelial cells (Figure 1).
All three cell types related to brain microvasculature 
were stained for ApoB, suggesting the presence of the 
protein (Figure 2). Quantification revealed a significantly 
stronger staining intensity in brain endothelial cells from 
transgenic mice as compared to wild type. No such differ-
ence was detected in the other two cell types.
Effects of oxidized LDL on viability of cultured brain 
endothelial cells, pericytes and glial cells from wild type 
and ApoB‑100 transgenic mice
Treatment with oxLDL resulted in cell damage in all 
three cell types. Impedance measurement showed that 
oxLDL exerted a dose- and time-dependent reduction 
in cell viability (Figures 3, 4). Elevated LDH release indi-
cates cell membrane injury at 24 h in all treated groups 
(Figure  4). Astroglia cells proved to be the most sensi-
tive to oxLDL treatments while pericytes were the least 
affected. Brain endothelial and glial cells from ApoB-100 
transgenic mice showed smaller reduction in viability and 
membrane damage compared to their wild type controls. 
In contrast to oxLDL, LDL treatment elevated the imped-
ance of cells reflecting a positive effect on viability and 
cell growth. No effect of LDL was found on LDH release 
confirming its non-toxic property. Primary pulmonary 
endothelial cells isolated from wild type and ApoB-100 
transgenic mice were also damaged by oxLDL treatment 
measured by impedance, but no difference was seen 
between the sensitivity of the cells from the two groups 
of animals (Additional File 1: Figure S1).
Effects of oxidized LDL on ROS and NO production 
in cultured brain endothelial cells, pericytes and glial cells 
from wild type and ApoB‑100 transgenic mice
Treatment with oxLDL significantly increased ROS pro-
duction in brain endothelial cells, pericytes and glial cells 
(Figure  5). In endothelial cells and pericytes, basal ROS 
production and ROS production after oxLDL treatment 
was higher in cells from ApoB-100 transgenic mice com-
pared to wild type, but no such effect was seen for NO. 
NO production was only elevated at the highest treat-
ment concentrations of oxLDL in endothelial cells and 
pericytes, but it resulted in an increase in NO production 
even from the lowest treatment concentration in astro-
glial cells (Figure 5). LDL treatment had no effect on ROS 
or NO production in these cultured cells.
Effects of oxidized LDL on the barrier integrity 
of co‑culture BBB models from wild type and ApoB‑100 
transgenic mice
When cells reached 264  ±  33  Ω  cm2 TEER value on 
the 4th day of co-culture, the effect of oxLDL treatment 
(24 h) was tested on the triple co-culture models of the 
BBB using Evans blue labeled albumin as marker mol-
ecule of transendothelial permeability (Figure  6). Low 
concentrations of oxLDL did not change the flux of 
albumin, but higher treatment concentrations (150 and 
200 µg/ml) significantly elevated the albumin penetration 
across cell layers in both groups. No significant change 
was observed in the electrical resistance of the models 
between the control and the treatment groups (Figure 6). 
There was no difference between the resistance of the 
BBB models from wild type (262 ± 30 Ω cm2) or ApoB-
100 transgenic (266 ± 37 Ω cm2) mice or in their albu-
min permeability (Figure 6).
We treated primary brain endothelial cells from both 
groups of mice with two concentrations of oxLDL (100 
and 200 µg/ml) and stained them for junctional proteins 
claudin-5, occludin and β-catenin (Figure  7). The junc-
tional staining changed in oxLDL treated cells, both the 
intensity and localization was altered compared to con-
trol conditions indicating barrier disturbance. We found 
no labeling of cell nuclei with ethidium-homodimer-1 
indicating no cell death, while all cell nuclei were labeled 
with bis-benzimide (H33343).
Effects of oxidized LDL on membrane fluidity of brain 
endothelial cells from wild type and ApoB‑100 transgenic 
mice
Membrane fluidity of living brain endothelial cells was 
determined by the measurement of fluorescence anisot-
ropy of the cationic membrane probe TMA-DPH (Fig-
ure 8). Anisotropy of both LDL and oxLDL treated wild 
type cells was elevated compared to the control. Treat-
ment with oxLDL increased anisotropy more than the 
treatment with LDL, indicating higher membrane rigid-
ity. The anisotropy of brain endothelial cells from ApoB-
100 transgenic mice was significantly higher than that of 
wild type cells which was not changed by treatment with 
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Figure 1 Characterization of cultured brain microvascular cells from wild type (Wt) and ApoB‑100 transgenic (Tg) mice. a Immunostaining of brain 
endothelial cells for transmembrane junctional protein claudin‑5 (Cl‑5) and occludin (Occl), and cytoplasmic linker proteins β‑catenin (β‑cat) and 
zonula occludens‑1 (ZO‑1). Astroglia cells were labeled for glial fibrillary acidic protein (GFAP), pericytes were stained for α‑smooth muscle (α‑SM) 
actin. Blue cell nuclei. Scale bar 15 µm. b Fluorescent intensity evaluation of immunostainings with ImageJ software shown as percentage of the 
labeling intensity of wild type cells. Values presented are mean ± SD, n = 8–16. Statistical analysis: two‑way ANOVA followed by Bonferroni post‑
test, *p < 0.05, ***p < 0.001 wild type compared to transgenic group.
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LDL or oxLDL. The membrane fluidizer benzyl alco-
hol quickly and greatly reduced the anisotropy (cells: 
0.320 ± 0.011 vs. benzyl alcohol: 0.307 ± 0.011).
Discussion
ApoB-100 transgenic mice fed cholesterol high diet 
have been used for a long while to study cardiovascu-
lar diseases [6]. Recently, cognitive impairment caused 
by dyslipidemia and/or hyperlipidemia was reported 
in this model [10, 28]. The BBB is the primary target of 
deteriorative changes caused by dyslipidemia and/or 
hyperlipidemia eventually leading to the development 
of neurodegeneration and dementia [29]. Brain capil-
lary injury including morphological changes in brain 
endothelial and swelling of astrocytic endfeet were 
seen in hyperlipidemic transgenic mice after ischemic 
challenge [11]. The role of pericytes was also recently 
revealed in cerebrovascular pathology in hyperlipidemic 
mice [30]. Although, there is accumulating evidence 
of harmful effects of hyperlipidemia on the BBB, very 
Figure 2 ApoB‑100 immunohistochemistry in cultured brain microvascular cells from wild type (Wt) and transgenic (Tg) mice. a Immunostain‑
ing for ApoB‑100 in brain endothelial cells, pericytes and astroglia cells. Green ApoB‑100 staining. Blue cell nuclei. Scale bar 15 µm. b Fluorescent 
intensity evaluation for ApoB‑100 immunostaining with ImageJ software shown as percentage of the labeling intensity of wild type cells. Values 
presented are mean ± SD, n = 10–15. Statistical analysis: two‑way ANOVA followed by Bonferroni post‑test, **p < 0.01 wild type compared to 
transgenic group.
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limited information is available on the phenotypic, mor-
phological and functional changes of the BBB at the cel-
lular level. Therefore in the present study morphological 
phenotypes of cultured brain endothelial cells, pericytes 
and glial cells isolated from ApoB-100 transgenic and 
wild type mice were investigated.
ApoB-100 is expressed mainly in the liver, intestine 
and heart [31, 32]. However, the presence of ApoB-100 
protein was demonstrated in the membrane microdo-
mains of primary brain endothelial cells using mass spec-
trometry [33]. Here, we confirm this result and using 
immunohistochemistry we show that ApoB-100 is appar-
ently present in brain endothelial cells. Although further 
experiments may be necessary to confirm this result, 
we suggest that ApoB-100 is synthesized in these cells. 
The transgenic construct contained the whole genomic 
Figure 3 Effects of low density lipoprotein (LDL) and oxidized LDL on cell viability: impedance measurement. Effects of LDL or oxLDL treatment on 
the cell viability of wild type (Wt) and transgenic (Tg). a Primary mouse brain endothelial cells (EC), b pericytes (PC) and c astroglia cells (AC) over 
24 h. Impedance is calculated from the normalized cell index which reflects cell viability. C control, OX oxLDL treatment; TX Triton‑X100 detergent. 
Values presented are mean ± SD, n = 3–7.
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ApoB-100 sequences (43 kb) including all the 29 introns 
and a 19 kb long 5′ and 14 kb long 3′ sequences providing 
all putative regulatory elements for correct tissue-specific 
gene expression [34]. Therefore, the expression of human 
ApoB-100 protein in transgenic mice reflects the endoge-
nous expression of the mouse gene. Indeed, neither others 
Figure 4 Effects of low density lipoprotein (LDL) and oxidized LDL on cell viability: impedance and lactate dehydrogenase (LDH) release. Effects of 
LDL or oxLDL treatment on the viability of cultured cells from wild type (Wt) and ApoB‑100 transgenic (Tg) mice. A Normalized cell index reflect to 
the viability of the cells 24 h after treatment. Viability of brain endothelial cells (EC), pericytes (PC) and astroglia cells (AC) is presented after LDL or 
oxLDL treatment. B Lactate dehydrogenase release of the cells 24 h posttreatment. C control, OX oxLDL treatment, TX Triton‑X100 detergent. Values 
presented are mean ± SD, n = 3–7. Statistical analysis: ANOVA followed by Dunnett and Bonferroni tests. Statistically significant differences: (a) 
compared to wild type control; (b) compared to transgenic control; *p < 0.05; **p < 0.01; ***p < 0.001 wild type compared to transgenic group.
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nor we have experienced any ectopic expression using this 
transgenic construct [34]. Further supporting the present 
observation the cerebrovascular/perivascular localiza-
tion of ApoB-100 in transgenic mice was demonstrated 
in our recent paper [10]. In addition to de novo synthesis, 
ApoB-100 uptake into brain endothelial cells can also be 
considered. In a parallel in vivo experiment we detected a 
nearly three-fold increase in the expression level of Lox1 
Figure 5 Effects of low density lipoprotein (LDL) and oxLDL treatment on ROS and NO production. Effects of LDL or oxLDL treatment on the 
reactive oxygen species (ROS) and nitric oxide (NO) production in cells from wild type (Wt) and ApoB‑100 transgenic (Tg) mice. A ROS and B NO 
production of brain endothelial cells (EC), pericytes (PC) and astroglia cells (AC) is shown 1 h after treatment. Hydrogen peroxide (H2O2) served as 
positive control in the ROS assay, sodium nitroprusside (SNP) served as positive control in the NO assay. C untreated control, OX oxLDL treatment. 
Values presented are mean ± SD, n = 3–8. Statistical analysis: ANOVA followed by Dunnett and Bonferroni tests. Statistically significant differences: 
(a) compared to wild type control; (b) compared to transgenic control; *p < 0.05; **p < 0.01; ***p < 0.001 wild type compared to transgenic.
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gene in isolated microvessels from transgenic mouse 
brains using qPCR, which may indicate enhanced trans-
port of lipoproteins into the cells of the BBB (Lénárt et al. 
2015 unpublished). Several groups have used the ApoB or 
ApoB-binding domain for brain targeting of nanoparti-
cles across the BBB [35, 36], which also indicates an active 
uptake/transport of ApoB-100 in brain endothelium 
in  vivo. A long-term saturated fat diet in mice induces 
neurovascular inflammation and brain capillary dysfunc-
tion measured by the brain extravasation of plasma pro-
teins ApoB and immunoglobulin G [37].
Using immunofluorescence, no obvious morphological 
differences were detected between genotypes concern-
ing glial cells, brain pericytes and endothelial cells. While 
no change was observed for transmembrane junctional 
proteins, the fluorescence intensity of the junctional 
cytoplasmic linker proteins, ZO-1 and β-catenin was 
higher in brain endothelial cells derived from transgenic 
mice but resistance values were not different between 
BBB models from the two groups of mice. Based on 
our data, the intensity differences in ApoB-100, ZO-1 
and β-catenin immunohistochemistry in cultured brain 
endothelial cells from ApoB-100 transgenic mice as com-
pared to wild type may not have functional significance 
for barrier integrity of the BBB model.
Hyperlipidemia causes oxidative stress which dam-
ages cerebral capillaries [10]. Therefore, the sensitivity of 
primary cells to oxLDL treatment was assessed. OxLDL 
accumulates in the atherosclerotic lesions of humans 
[38] and is also present in ApoE−/− mice [39]. OxLDL 
was identified as initiator of endothelial dysfunction [40]. 
We found that the sensitivity of brain endothelial cells, 
pericytes and glial cells to oxLDL (50–200 µg/ml) treat-
ment is largely different. Astrocytes and endothelial cells 
were found to be the more vulnerable to oxLDL treat-
ment compared to pericytes. A dose-dependent reduc-
tion in cell impedance was observed for all treated cell 
types. Our observation is consistent with the results of 
previous reports describing the toxic effect of oxLDL 
on brain endothelial cells [41] and retinal pericytes [42]. 
Primary pulmonary endothelial cells, which do not form 
a tight barrier, were also damaged by oxLDL treatment. 
Furthermore, oxLDL caused barrier dysfunction and 
alterations in junctional morphology of brain endothe-
lial cells in triple co-culture BBB models in accordance 
to literature data on mouse brain monolayers [43, 44]. 
Our results indicate that the transcellular transport of 
albumin is increased after oxLDL treatment. Similar 
effects, no change in paracellular transport but elevation 
in albumin transfer, were seen after hypoxia [45] or his-
tamine treatment [46] in BBB co-culture models. There 
was no difference between the basal barrier function of 
the BBB models from wild type and ApoB-100 transgenic 
mice, in concordance with the similarity of morphology 
and immunostaining intensity of transmembrane tight 
junctional proteins in brain endothelial cells from both 
groups.
Interestingly, transgenic brain endothelial cells and 
astrocytes showed smaller reduction in viability and 
increased resistance to membrane damage compared 
to wild-type cells indicating certain protection against 
oxLDL-induced cytotoxicity in cultured cells derived 
from ApoB-100 transgenic animals. No difference was 
seen between the sensitivity of peripheral (pulmonary) 
endothelial cells from the two groups of mice. To reveal 
the possible mechanism behind this phenomenon, 
NO and ROS production was monitored in these cells 
Figure 6 Effects of low density lipoprotein (LDL) and oxLDL on the 
barrier integrity of co‑culture BBB models. Effects of LDL or oxLDL 
treatment on the barrier integrity of BBB models from wild type 
(Wt) and ApoB‑100 transgenic (Tg) mice. Brain endothelial cells co‑
cultured with pericytes and astroglia cells were treated for 24 h with 
LDL or oxLDL. A Permeability of mouse brain endothelial cell layers 
for Evans blue labeled albumin (EBA) is expressed as endothelial 
permeability coefficient (Pe, cm/s). B Transendothelial electrical resist‑
ance (TEER) is expressed as Ω cm2. C untreated control, OX oxLDL 
treatment. Values presented are mean ± SD, n = 3. Statistical analysis: 
ANOVA followed by Dunnett and Bonferroni post‑tests. Statistically 
significant differences: (a) p < 0.05 compared to wild type control; (b) 
p < 0.05 compared to transgenic control.
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during oxLDL treatment. OxLDL induces production 
of reactive oxygen and nitrogen species and the result-
ing oxidative stress leads to endothelial dysfunction 
and consequently to atherosclerosis and cardiovascular 
diseases [47]. A significant increase in ROS production 
was detected in all cell types after oxLDL treatment. 
These results are in agreement with previous work of 
Chang et al. [48] who also showed a similar increase in 
ROS production after oxLDL treatment in mouse brain 
endothelial cells. ROS production induced by oxLDL in 
human umbilical vein endothelial cells was increased via 
the enhanced activity of NADPH oxidase and reduced 
activity of superoxide dismutase and catalase [49]. Mito-
chondrial damage due to increased reactive oxygen and 
nitrogen species formation in response to oxLDL treat-
ment was also reported in bovine aortic endothelial 
cells [50]. Interestingly, in endothelial cells and peri-
cytes, basal ROS production and ROS production after 
oxLDL treatment were higher in cells from ApoB-100 
transgenic mice compared to wild type indicating that 
the protective effect seen in viability studies is not medi-
ated by lower production of ROS. OxLDL promotes 
the generation of superoxide that reduces the activity 
Figure 7 Effect of oxLDL on junctional stainings in cultured brain microvascular cells from wild type (Wt) and transgenic (Tg) mice. Immunostain‑
ing of brain endothelial cells for transmembrane junctional protein claudin‑5 (Cl‑5) and occludin (Occl), and cytoplasmic linker protein β‑catenin 
(β‑cat) after 100 and 200 µg/ml oxLDL treatment or in untreated controls (C). Red color junctional immunostaining. Blue cell nuclei. Scale bar 25 µm.
Figure 8 Effects of low density lipoprotein (LDL) and oxLDL on 
membrane fluidity of brain endothelial cells measured as anisotropy. 
Effects of oxLDL or LDL treatment on the membrane fluidity of 
cultured brain endothelial cells from wild type (Wt) and ApoB‑100 
transgenic (Tg) mice. Effects were measured by TMA‑DPH fluores‑
cence anisotropy on cell suspensions after overnight treatment with 
10 µg/ml LDL or oxLDL treatment. C untreated control, OX oxLDL 
treatment. Values presented are mean ± SD, n = 3. Statistical analysis: 
ANOVA followed by Dunnett and Bonferroni post‑tests. Statistically 
significant differences: (a) p < 0.001 compared to wild type control; 
(b) p < 0.001 compared to LDL treated wild type cells; *p < 0.05; 
**p < 0.01; ***p < 0.001 wild type compared to transgenic group.
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of endothelial nitric oxide synthase thus decreasing the 
amount of NO in peripheral endothelial cells [51]. In the 
present study, high concentrations of oxLDL increased 
the production of NO in all three cell types of the brain 
microvasculature. These are the first data on cultured 
brain endothelial cells, pericytes and glial cells and the 
results are different from observations on the effect of 
oxLDL on peripheral endothelial cells. Although no 
comparative data are available, cells related to cerebral 
vasculature may differ from peripheral endothelial cells 
in several aspects including NO production. NO plays a 
central role in cerebrovascular regulation and all cells of 
the neurovascular unit contribute to its production by a 
complex network of regulation [52].
Lipid enriched membrane microdomains in brain 
endothelial cells contribute to BBB functions including 
cell polarity, paracellular barrier formation, transport 
pathways and signalling [33]. These microdomains are 
enriched in cholesterol and sphingolipids [53]. Mem-
brane cholesterol and rafts are modified by oxLDL [54]. 
Oxysterols, responsible for the toxic effect of highly oxi-
dized LDL, are incorporated into the plasma membrane 
thus perturbing the distribution of cholesterol-rich 
membrane microdomains [55]. Changes in plasma mem-
brane fluidity may reflect disturbances in membrane 
cholesterol and rafts, therefore living brain endothelial 
cells were examined for TMA-DPH fluorescence anisot-
ropy for the first time. Treating wild type brain endothe-
lial cells with native or oxLDL resulted in remarkable 
increase in anisotropy, indicating higher level of mem-
brane rigidity. The membrane of brain endothelial cells 
from transgenic animals was significantly stiffer than in 
wild type mice. This apparent high membrane rigidity of 
transgenic cells was not changed further by treatment. 
In agreement with our results, oxLDL also reduced the 
fluidity of the outer membrane layer of platelets [56]. 
While it is known that changes in plasma membrane 
fluidity and lipid rafts are linked to cell death [57], fur-
ther experiments are needed to clarify the importance of 
the increased membrane rigidity in cells from ApoB-100 
transgenic animals.
Conclusion
The morphological and functional properties of cultured 
brain endothelial cells, pericytes and glial cells from 
ApoB-100 transgenic mice were characterized and com-
pared to wild type cells for the first time. The presence of 
ApoB-100 was confirmed in brain endothelial cells, while 
no gross morphological change was observed between 
wild type and transgenic cells. Oxidized but not native 
LDL exerted dose-dependent toxicity in all three cell 
types, induced barrier dysfunction and increased ROS 
production in both genotypes. A partial protection from 
oxLDL toxicity was seen in brain endothelial and glial 
cells from ApoB-100 transgenic mice. Increased mem-
brane rigidity was measured in brain endothelial cells 
from ApoB-100 transgenic mice and in LDL or oxLDL 
treated wild type cells indicating alterations in lipid com-
position. To understand the link between membrane flu-
idity and increased growth kinetics and partial protection 
in ApoB-100 transgenic cells related brain microvascula-
ture further experiments are needed.
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